Q2 EPS Estimate for CRISPR Therapeutics Boosted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - HC Wainwright lifted their Q2 2025 EPS estimates for CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.93) per share for the quarter, up from their previous estimate of ($1.01). HC Wainwright has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. HC Wainwright also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.07) EPS and FY2025 earnings at ($4.57) EPS.

Several other equities analysts have also weighed in on CRSP. Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Barclays decreased their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Friday. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target on the stock in a research report on Wednesday, February 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded down $0.37 during trading hours on Monday, reaching $37.22. 2,024,125 shares of the company were exchanged, compared to its average volume of 1,668,717. The stock has a 50 day simple moving average of $38.03 and a 200 day simple moving average of $42.64. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -8.52 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.43) EPS.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 9,973 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the sale, the chief executive officer now directly owns 180,890 shares in the company, valued at $7,673,353.80. This represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.30% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Wealth Enhancement Advisory Services LLC boosted its holdings in CRISPR Therapeutics by 19.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 36,139 shares of the company's stock worth $1,422,000 after purchasing an additional 5,898 shares during the last quarter. Green Alpha Advisors LLC grew its position in CRISPR Therapeutics by 28.6% in the fourth quarter. Green Alpha Advisors LLC now owns 24,629 shares of the company's stock valued at $969,000 after purchasing an additional 5,471 shares in the last quarter. AdvisorNet Financial Inc lifted its position in CRISPR Therapeutics by 91.1% during the 4th quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company's stock worth $98,000 after buying an additional 1,181 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in shares of CRISPR Therapeutics by 18.4% in the 4th quarter. 180 Wealth Advisors LLC now owns 5,167 shares of the company's stock valued at $203,000 after acquiring an additional 803 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.